Ingredient · Active Botanical Compound

Active Botanical Compound

Active Botanical Compound

Family Hymenogastraceae · Compound class: tryptamine alkaloids (Active Botanical alkaloids).

MYKO's premium framing for the Active Botanical present in NEUROGENESIS, EMBODY, and CORTEX.

MYKO Spec
100mg per Capsule
Used In
NEUROGENESIS · EMBODY · CORTEX
Evidence
Tier 3–4 Microdose

MYKO's premium Active Botanical Compound — included at low dose within an intentional, cyclable ritual practice, framed as wellness scaffolding rather than as a clinical treatment.

What It Is

MYKO's premium framing for the Active Botanical in three formulas.

The Active Botanical Compound used in NEUROGENESIS, EMBODY, and CORTEX is the Active Botanical — a well-characterized strain that is among the most studied of the Active Botanical family in research and traditional contexts.

MYKO uses 100mg of dried, milled fruiting body per capsule. Note: this is sub-perceptual at a single capsule and is not a clinical dose. Therapeutic-dose research (used in dedicated clinical settings under medical supervision) is materially different from the low-dose preparation used in MYKO.

The botanical chemistry includes the Active Botanical compound, which the body converts to the Active Botanical metabolite, the active form. MYKO products are not clinical treatments and have not been clinically evaluated for any condition.

Why MYKO Uses It

The second arm of the neurotrophin thesis.

MYKO uses the Active Botanical Compound to engage the second arm of NEUROGENESIS's neurotrophin thesis — pairing Lion's Mane (NGF pathway) with the Active Botanical (BDNF / TrkB / mTOR pathway literature) inside a single capsule. In EMBODY, it accompanies a restorative mushroom stack. In CORTEX, it accompanies a calm-vigilance Cordyceps + Reishi pairing.

Within all three formulas, MYKO frames the Active Botanical as a contemplative, low-dose ritual ingredient — not a treatment for any condition. Customer copy emphasizes preparation, intention, and cycling, not outcome promises.

Found In MYKO Formulas

Where Active Botanical Compound appears in the line.

NEUROGENESIS
The Brain
100mg per capsule · paired with Lion's Mane
View Formula →
EMBODY
The Foundation
100mg per capsule · paired with Chaga + Reishi + Turkey Tail
View Formula →
CORTEX
The Shield
100mg per capsule · paired with Cordyceps + Reishi
View Formula →
Effects & Experience

Sub-perceptual ritual — scaffolding, not spectacle.

Within MYKO formulas, low-dose Active Botanical use is intended to be sub-perceptual — not visionary. Customers most often describe small adjustments to baseline: subtle openness, gentle mood and motivation lift, occasional novelty in thinking. Many customers describe protocols as supportive scaffolding rather than as discrete experiences.

Effects are highly individual. Some customers report no perceptible change. Mood, cognition, and emotional outcomes are not guaranteed. Set, setting, sleep, stress load, and current medications all influence response.

Key Bioactive Compounds

The chemistry MYKO selects for.

  • Psilocybin
    A prodrug tryptamine alkaloid. Rapidly converted to the Active Botanical metabolite via alkaline phosphatase after ingestion. Average content in dried Active Botanical: ~0.5–2% by weight.
  • Psilocin
    The active metabolite. A non-selective serotonin receptor agonist with high affinity for the 5-HT2A receptor. Metabolized by UGT 1A10 / 1A9.
  • Baeocystin & norsupporting alkaloid
    Minor tryptamine alkaloids that may contribute to the overall pharmacology profile in research literature.
  • Beta-glucans & ergosterol
    Fungal cell-wall and sterol compounds present in any whole-fruiting-body preparation.
Mechanisms in the Body

Three pathways, three evidence levels.

Mechanism strength is presented separately so you can see what is human-supported, what is preclinical, and what is traditional theory.

Human-Supported
  • Therapeutic-dose research (conducted at clinical doses in supervised settings, materially different from MYKO low-dose capsules): a body of randomized human research has examined Active Botanical compounds in dedicated clinical contexts. Outcomes from those settings should not be implied for MYKO products.
  • Microdose-specific human evidence is currently limited and mixed. Several placebo-controlled microdose trials have reported expectancy effects rather than consistent active drug effects on mood or cognition.
Preclinical / Mechanistic
  • 5-HT2A agonism initiates BDNF/TrkB and mTOR signaling — pathways associated with neuroplasticity and synaptic remodeling in research literature.
  • Increases dendritic spine density in hippocampal and prefrontal cortex regions in animal models, with effects detectable beyond a week post-administration in some studies (Du et al., 2023; Weiss et al., 2025).
  • Acutely suppresses default-mode-network (DMN) activity in human imaging studies — relevant to research-context cognitive flexibility, not implied as a MYKO product effect.
  • Anti-inflammatory effects mediated by 5-HT2A receptor activity have been observed at sub-perceptual doses in preclinical models.
Traditional / Theoretical
  • Active Botanical compounds appear in Indigenous traditions of Mesoamerica with documented continuity, particularly in Mazatec ceremonial practice, where preparation and integration are central to use. MYKO acknowledges this lineage with respect; MYKO products are a modern preparation and are not a substitute for traditional ceremonial context.
Evidence Grade

How MYKO grades this ingredient.

Overall Grade
Therapeutic-dose research in supervised clinical contexts: Tier 1 in those contexts (not transferable to MYKO). · Microdose-specific evidence: Tier 3–4. · Long-form preclinical neuroplasticity evidence: Tier 3.
Strongest Areas
5-HT2A pharmacology (Tier 1); BDNF/TrkB and mTOR pathway literature (Tier 2–3 preclinical); long-form neuroplasticity in animal models (Tier 3); decades of community use (Tier 4 weight, large dataset).
Weaker / Emerging
Microdose human outcome trials (mixed, often expectancy-driven); standalone mood, anxiety, or trauma claims; specific cognitive-performance percentages.
Claim Caution
High
Reason
Therapeutic-dose research is among the most exciting in modern psychiatry, but is not what MYKO sells. Microdose-specific human evidence is genuinely emerging. The brand voice must keep these contexts separate, frame MYKO products as wellness rituals (not treatments), and respect cycling, contraindications, and customer screening.
Science Hub

For the customer who wants the full picture.

Read the Deeper Technical Version

The Active Botanical Compound in NEUROGENESIS, EMBODY, and CORTEX is dried, milled fruiting body of the Active Botanical. Its pharmacology is led by the Active Botanical compound, a tryptamine prodrug rapidly converted to the Active Botanical metabolite by alkaline phosphatase. Psilocin is a non-selective serotonin receptor agonist with high affinity for 5-HT2A in the cortex; it engages BDNF/TrkB and mTOR pathway literature associated with neuroplasticity and dendritic spine growth.

It is essential to keep two contexts separate: therapeutic-dose research (conducted at supervised clinical doses in dedicated settings) is not the context MYKO products operate in, and outcomes from that context should not be implied for low-dose MYKO use. Microdose-specific human evidence is currently mixed; several placebo-controlled trials have reported expectancy effects rather than reliable active drug effects, while preclinical neuroplasticity evidence at low doses remains promising.

Within MYKO formulas, the Active Botanical Compound appears at 100mg of dried fruiting body — a sub-perceptual single-capsule dose intended for protocol-driven, cyclable ritual use. NEUROGENESIS pairs it with Lion's Mane to engage two complementary neurotrophin literatures. EMBODY pairs it with a Chaga / Reishi / Turkey Tail restorative stack. CORTEX pairs it with Cordyceps and Reishi for a calm-vigilance profile.

MYKO's Stamets (4 on / 3 off) and Fadiman (1 on / 2 off) cycling guidance, lithium contraindication, SSRI / SNRI cautions, and Bipolar I / psychosis screening are non-negotiable. MYKO products are not clinical treatments and have not been clinically evaluated for any condition. See Section 6 for full safety language.

References cited on this page (2)

Citations referenced inline in the mechanisms and technical sections above. For the full evidence base across all MYKO ingredients, see the Library. Sources are listed by author and year only — full citation details available on request.

  1. Du et al., 2023
  2. Weiss et al., 2025
Safety Notes

What to know before using.

  • ABSOLUTE contraindication — Lithium: Reports of seizures, cardiac events, and death. Never combine.
  • ABSOLUTE caution — Personal or family history of psychosis, schizophrenia, or Bipolar I: Active Botanical use can trigger psychotic or manic episodes. Screen all customers; not appropriate for these populations.
  • MAOIs: Risk of serotonergic excess. Avoid combination.
  • SSRIs / SNRIs: May significantly blunt response (47–55% in research literature) and may remain dampened for 3–6 months after discontinuation. Active Botanical use is generally not advised on SSRIs / SNRIs.
  • Lion's Mane is a weak MAOI: triple-serotonergic risk if combined with SSRIs. Avoid SSRIs in any MYKO Active Botanical stack.
  • Pregnancy / breastfeeding: Not appropriate. No safety data.
  • Cardiovascular conditions: Use caution. 5-HT2A activity affects cardiovascular tone.
  • Tolerance builds rapidly within 2–3 days; protocol cycling is essential. MYKO supports Stamets (4 on / 3 off) and Fadiman (1 on / 2 off) frameworks.
  • Legal status varies by jurisdiction. MYKO customers are responsible for verifying local applicable regulations.
  • MYKO products are not clinical treatments and have not been clinically evaluated for any condition.
Research Notes

What's supported, what's emerging.

What is reasonably supported (in research, not as MYKO product claims): therapeutic-dose efficacy in supervised clinical research; 5-HT2A pharmacology; BDNF/TrkB-pathway involvement; long-form neuroplasticity in animal models; acute DMN suppression in human imaging.

What is still emerging: microdose-specific outcome literature; durability of low-dose neurotrophin effects; standardized cycling protocols.

What should not be claimed strongly: "treats depression," "cures anxiety," "heals trauma," "guarantees neuroplasticity," "replaces therapy or medication," "is psychedelic therapy," or any framing that conflates therapeutic-dose research with the MYKO product experience.

Where more human research is needed: properly powered microdose RCTs; sex differences; long-term safety of repeated low-dose use over years; cycling-protocol comparative efficacy.

Where It Leads

Meet the formulas built on it.

Every MYKO ingredient earns its place in a formula. See the systems it powers — or find the one built for you.

Shop The Formulas Find Your Formula
Explore Ingredients

All Twelve in MYKO's Library.

Lion's Mane Cordyceps Shilajit Reishi Chaga Turkey Tail Active Botanical P. Ochra 5 Mushroom Complex Niacin · B3 Magnesium Glycinate Magnesium L-Threonate

These statements have not been evaluated by the U.S. Food and Drug Administration. MYKO products are not intended to diagnose, treat, cure, or prevent any disease.

Information on this site is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Consult a qualified healthcare practitioner before beginning any new supplement, particularly if you are pregnant, breastfeeding, taking medication, or managing a medical condition.